


"Express Mail" mailing label number EL 856 148 211 US I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on September 17, 2001.

By: Clara Alcazar

Printed: Clara Alcazar



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Y. Tom Tang; Neil C. Corley; Karl J. Guegler; Chandra Arvizu;
Mariah R. Baughn

Title: THIOREDOXIN PROTEINS

Serial No.: To Be Assigned

Filing Date: Herewith

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Commissioner for Patents
Box Patent Applications
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 09/107,248 filed June 30, 1998 from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant

and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.


It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.



David G. Streeter, Ph.D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

Date: September 17, 2001

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				FF-0556-1 DIV		To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANTS				Applicant(s)			
(Use several sheets if necessary)				Tang et al.			
				Filing Date		Group	
				Herewith		To Be Assigned	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Foreign Patent Documents							
							Translation
		Document	Date	Country	Class	Subclass	Yes No
	1	WO 99/18204	15 April 1999	WO			
	2	WO 98/45756	22 Oct. 1998	WO			
	3	WO 98/07749	26 Feb. 1998	WO			
	4	WO 99/09061	25 Feb. 1999	WO			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Sen, C.K. and L. Packer, "Antioxidant and redox regulation of gene transcription", <u>FASEB J.</u> , 10: 709-720 (1996)					
	2	Schreck, R. et al., "Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF- κ B transcription factor and HIV-1", <u>EMBO J.</u> , 10: 2247-2258 (1991)					
	3	Kalebic, T. et al., "Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine", <u>Proc. Natl. Acad. Sci.</u> , 88: 986-990 (1991)					
	4	Abate, C. et al., "Redox Regulation of Fos and Jun DNA-Binding Activity in Vitro", <u>Science</u> , 249: 1157-1161 (1990)					
	5	Rosen, A. et al., "A CD4 ⁺ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin", <u>Int. Immunol.</u> , 7: 625-633 (1995)					
Examiner			Date Considered				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.</p>							

	6	Tagaya, Y. et al., "ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction", <u>EMBO J.</u> , 8: 757-764 (1989)
	7	Newman, G.W. et al., "Opposing Regulatory Effects of Thioredoxin and Eosinophil Cytotoxicity-enhancing Factor on the Development of Human Immunodeficiency Virus 1", <u>J. Expt. Med.</u> 180: 359-363 (1994)
	8	Makino, Y. et al., "Thioredoxin: a Redox-regulating Cellular Cofactor for Glucocorticoid Hormone Action", <u>J. Clin. Invest.</u> , 98: 2469-2477 (1996)
	9	Andersson, B. et al., (GI 4406577), GenBank Sequence Database (Accession AAD20035), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland 20894, 26 February 1999.
Examiner		Date Considered
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.</p>		